Immuron Limited-Product Pipeline Review-2015

Immuron Limited-Product Pipeline Review-2015

  • Products Id :- GMDHC07721CDB
  • |
  • Pages: 26
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Immuron Limited-Product Pipeline Review-2015


Global Markets Direct's, 'Immuron Limited-Product Pipeline Review-2015', provides an overview of the Immuron Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immuron Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Immuron Limited including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Immuron Limited's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Immuron Limited's pipeline products

Reasons To Buy

Evaluate Immuron Limited's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Immuron Limited in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Immuron Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Immuron Limited and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immuron Limited

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Immuron Limited and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Immuron Limited Snapshot 5

Immuron Limited Overview 5

Key Information 5

Key Facts 5

Immuron Limited-Research and Development Overview 6

Key Therapeutic Areas 6

Immuron Limited-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Immuron Limited-Pipeline Products Glance 10

Immuron Limited-Clinical Stage Pipeline Products 10

Phase II Products/Combination Treatment Modalities 10

Immuron Limited-Early Stage Pipeline Products 11

Preclinical Products/Combination Treatment Modalities 11

Discovery Products/Combination Treatment Modalities 12

Immuron Limited-Drug Profiles 13

IMM-124E 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

Antibody for Colitis 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

IMM-160 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

IMM-363 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

IMM-529 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

IMM-252 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Immuron Limited-Pipeline Analysis 20

Immuron Limited-Pipeline Products by Route of Administration 20

Immuron Limited-Pipeline Products by Molecule Type 21

Immuron Limited-Recent Pipeline Updates 22

Immuron Limited-Dormant Projects 23

Immuron Limited-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Appendix 25

Methodology 25

Coverage 25

Secondary Research 25

Primary Research 25

Expert Panel Validation 25

Contact Us 25

Disclaimer 26

List of Tables

Immuron Limited, Key Information 5

Immuron Limited, Key Facts 5

Immuron Limited-Pipeline by Indication, 2015 7

Immuron Limited-Pipeline by Stage of Development, 2015 8

Immuron Limited-Monotherapy Products in Pipeline, 2015 9

Immuron Limited-Phase II, 2015 10

Immuron Limited-Preclinical, 2015 11

Immuron Limited-Discovery, 2015 12

Immuron Limited-Pipeline by Route of Administration, 2015 20

Immuron Limited-Pipeline by Molecule Type, 2015 21

Immuron Limited-Recent Pipeline Updates, 2015 22

Immuron Limited-Dormant Developmental Projects,2015 23

Immuron Limited, Other Locations 24

List of Figures

Immuron Limited-Pipeline by Top 10 Indication, 2015 7

Immuron Limited-Pipeline by Stage of Development, 2015 8

Immuron Limited-Monotherapy Products in Pipeline, 2015 9

Immuron Limited-Pipeline by Top 10 Route of Administration, 2015 20

Immuron Limited-Pipeline by Top 10 Molecule Type, 2015 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Immuron Limited; Immuron Limited-Key Therapeutics; Immuron Limited-Pipeline Overview and Promising Molecules; Immuron Limited-News; Immuron Limited-Latest Updates; Immuron Limited-Pipeline; Immuron Limited-Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 107820
Site License
USD 3000 INR 215640
Corporate User License
USD 4500 INR 323460



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]